InflaRx NV (IFRX)
0.926
-0.01
(-0.81%)
USD |
NASDAQ |
Feb 26, 16:00
0.926
0.00 (0.00%)
After-Hours: 17:33
InflaRx Research and Development Expense (Quarterly) : 7.293M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| CDT Equity, Inc. | 1.532M |
| LENZ Therapeutics, Inc. | 3.791M |
| Liminatus Pharma, Inc. | 0.00 |
| Oruka Therapeutics, Inc. | 28.99M |
| Maze Therapeutics, Inc. | 25.19M |